Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nrc Health (NRC) Cash & Equivalents (2016 - 2026)

Nrc Health's Cash & Equivalents history spans 16 years, with the latest figure at $4.1 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 2.22% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 2.22% decrease, with the full-year FY2025 number at $4.1 million, down 2.22% from a year prior.
  • Cash & Equivalents hit $4.1 million in Q4 2025 for Nrc Health, up from $2.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for NRC hit a ceiling of $54.4 million in Q4 2021 and a floor of $485000.0 in Q2 2024.
  • Historically, Cash & Equivalents has averaged $20.7 million across 5 years, with a median of $14.6 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 97.84% in 2024 and later surged 987.42% in 2025.
  • Tracing NRC's Cash & Equivalents over 5 years: stood at $54.4 million in 2021, then plummeted by 53.96% to $25.0 million in 2022, then tumbled by 73.42% to $6.7 million in 2023, then tumbled by 36.37% to $4.2 million in 2024, then dropped by 2.22% to $4.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for NRC at $4.1 million in Q4 2025, $2.2 million in Q3 2025, and $5.3 million in Q2 2025.